Hemostasis management of the cardiac surgical patient has changed following the withdrawal of aprotinin for use in cardiac surgical patients. The challenge to minimize blood loss and reduce exposure of cardiac surgical patients to blood products continues to grow with patients presenting being older and sicker and more complex procedures being performed. The cardiac surgery team has many options available for it to consider; although current recommendations strongly support the use of cell salvage as one process to assist in this challenge, other options need to be equally critically evaluated.
Westaby S.Aprotinin: twenty-five years of claim and counterclaim. J Thorac Cardiovasc Surg. 2008;135:487-491.
2.
US Food and Drug Administration.FDA requests marketing suspension of Trasylol. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01738.html. Published November 5, 2007. Accessed May 2008.
3.
Mangano DT, Tudor IC, Dietzel C.The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006; 3 54: 353-365.
4.
Karkouti K., Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion. 2006;46:327-338.
5.
Fergusson DA , Hebert PC, Mazer CD, et al A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-2331.
6.
US Food and Drug Administration .Manufacturer removes remaining stocks of Trasylol. http://www.fda.gov/bbs/topics/ NEWS/2008/NEW01834.html. Published May 14, 2008. Accessed April27, 2009.
7.
Grayson AD, Jackson M., Desmond MJMonitoring blood transfusion in patients undergoing coronary artery bypass grafting: an audit methodology. Vox Sang. 2003;85: 96-101.
8.
Puskas J., Cheng D., Knight J., et al. Off-pump versus conventional coronary artery bypass grafting: a meta-analysis and consensus statement from the 2004 I SMIC S Consensus Conference . Innovations: Tech Tech Cardiothorac Vasc Surg. 2005;1:3-27.
9.
Lau K., Shah H., Kelleher A., Moat N.Coronary artery surgery: cardiotomy suction or cell salvage? J Cardiothorac Surg. 2007;2:46.
10.
Brooker RF, Brown WR, Moody DM, et al. Cardiotomy suction: a major source of brain lipid emboli during cardiopulmonary bypass. Ann Thorac Surg. 1998 ;65: 1651-1655.
11.
Kaza AK, Cope JT, Fiser SM, et al. Elimination of fat microemboli during cardiopulmonary bypass . Ann Thorac Surg. 2003;75:555-559.
12.
Kincaid EH, Jones TJ, Stump DA, et al. Processing scavenged blood with a cell saver reduces cerebral lipid microembolization. Ann Thorac Surg. 2000;70: 1296-1300.
13.
Carless PA, Henry DA, Moxey AJ, O'Connell DL, Brown T., Fergusson DACell salvage for minimising perioperative allogeneic blood transfusion . Cochrane Database Syst Rev. 2006;(4):CD001888. doi:10.1002/14651858. CD001888.pub2.
14.
Shann KG, Likosky DS, Baker RA, et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: a focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg. 2006;132:283-290.
15.
Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(5, suppl):S27-S86.
16.
Amand T., Pincemail J., Blaffart F., Larbuisson R., Limet R., Defraigne JOLevels of inflammatory markers in the blood processed by autotransfusion devices during cardiac surgery associated with cardiopulmonary bypass circuit . Perfusion. 2002;17:117-123.
17.
Rubens FD, Boodhwani M., Mesana T., Wozny D., Wells G., Nathan HJ; Cardiotomy Investigators.The cardiotomy trial: a randomized, double blind study to assess the effect of processing of shed blood during cardiopulmonary bypass on transfusion and neurocogntivie function . Circulation. 2007;116(11 suppl):189-197.
18.
Djaiani G., Fedorko L., Borger MA, et al. Continuous-flow cell saver reduces cognitive decline in elderly patients after coronary bypass surgery. Circulation. 2007;116:1888-1895.
19.
Klein AA, Nashef SAM, Sharples L., et al. A randomized controlled trial of cell salvage in routine cardiac surgery. Anesth Analg. 2008;107:1487-1495.
20.
Jegger D., Horisberger J., Jachertz M., et al. A novel device for reducing hemolysis provoked by cardiotomy suction during open heart cardiopulmonary bypass surgery: a randomized prospective study. Artif Organs. 2007;31:23-30.
21.
Boodhwani M. , Williams K., Babaev A., Gill G., Saleem N., Rubens FDUltrafiltration reduces blood transfusions following cardiac surgery: a meta-analysis. Eur J Cardiothorac Surg. 2006;30:892-897.
22.
Naik SK, Knight A., Elliott M.A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery. Circulation. 1991;84(5 suppl): 111422-111431.
23.
Beckmann SR , Carlile D., Bissinger RC, Burrell M., Winkler T., Shely WWImproved coagulation and blood conservation in the golden hours after cardiopulmonary bypass. J Extra Corpor Technol. 2007;39:103-108.
24.
Laupacis A. , Fergusson D.Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg. 1997;85:1258-1267.
25.
Levi M., Cromheecke ME, deJonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999;354:1940-1947.
26.
Myles PS, Smith J., Knight J., Cooper DJ, McNeil J., Silbert B.Aspirin and tranexamic acid for coronary artery surgery: a randomized controlled trial. https://www.atacas.org.au. Accessed April 11, 2008.
27.
Landis C.Why thrombin PAR1 receptors are important to the cardiac surgical patient . J Extra Corpor Technol. 2007;39:305-307.
28.
Dunkley S., Phillips L., McCall P., et al. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg. 2008;85:836-844.
